Hans-Heinrich Henneicke-Von Zepelin
Research Subjects
Hans-Heinrich Henneicke-Von Zepelin has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Petra Stute
Abteilung für Gynäkologische Endokrinologie und Reproduktionsmedizin, Universitätsklinik für Frauenheilkunde, Inselspital Bern, Bern, Schweiz
3 shared publications Hagen Kelm
Department of Pneumology, Ruppin Hospital, Neuruppin, Germany
2 shared publicationsHenning Wege
Department of General Internal Medicine, Oncology/Haematology, Gastroenterology and Infectiology, Hospital Esslingen, Esslingen, Germany
2 shared publications- Ingmar Bergs
Department of Pneumology and Intensive Care Medicine, University Hospital RWTH Aachen, Aachen, Germany
2 shared publications Johannes-Josef Tebbe
Department of Gastroenterology and Infectiology, Hospital Lippe, Medical School and University Medical Center OWL, Bielefeld University, Bielefeld, Germany
2 shared publicationsMichael Dreher
Department of Pneumology and Intensive Care Medicine, RWTH Aachen University Hospital, Aachen, Germany
2 shared publications
Latest Publications
- Open Access
- 19 January 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (3) , 1367-1368
Correction to: Tiprelestat for Treatment of Hospitalized COVID-19: Results of the Double-Blind Randomized Placebo-Controlled COMCOVID Trial
- 19 January 2026
- Published by Springer Nature in Advances in Therapy
- Vol. 43 (3) , 1367-1368
Open AccessCorrection to: Tiprelestat for Treatment of Hospitalized COVID-19: Results of the Double-Blind Randomized Placebo-Controlled COMCOVID Trial
- Open Access
- 16 September 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (11) , 5683-5695
Tiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trial
Introduction Tiprelestat (recombinant human elafin) reversibly inhibits human neutrophil elastase. This can reduce overactivity of this enzyme in COVID-19-patients and might prohibit further organ damage and progression to severe disease. This protein had yet not been tested in COVID-19 patients. Methods This prospective, multicenter, randomized, double-blind, placebo-controlled trial investigated Tiprelestat in adult patients hospitalized for COVID-19 in 7 hospitals in Germany between May 2023 and May 2024. Patients received 100 mg Tiprelestat or placebo twice a day for 7 days, or shorter if no longer hospitalized due to COVID-19. Data about efficacy, safety, and pharmacokinetic trough levels were collected over 29 days. Results A total of 296 patients were planned. Due to slow recruitment during the end of the pandemic, only 17 patients were finally included. Of these, 9 received Tiprelestat and 8 placebo. The mean treatment exposition was 9.1 ± 4.8 (SD, maximum 15) 30-min infusions with Tiprelestat and 7.8 ± 3.2 (maximum 14) with placebo. No relevant abnormalities in clinical or laboratory blood parameters were suspected to be caused by Tiprelestat. None of the Tiprelestat-treated patients developed severe COVID-19 (WHO Clinical Progression Scale ≥ 6). The number of days with any oxygen support tended to be lower in the Tiprelestat group (2.4 ± 3.6 days) compared to placebo (4.0 ± 6.2 days). Stable plasma trough levels of Tiprelestat were shown upon repeated administration for up to 7 days, even in patients with impaired renal function (eGFR > 31 to < 60 mL/min) as comorbidity. Conclusion Tiprelestat infused for 30 min twice daily in patients with moderate COVID-19 requiring hospitalization was well tolerated and appears to be safe. Beneficially, plasma trough levels of the drug over time were high and stable. The small sample size does not facilitate reliable statements about efficacy. Further studies are necessary including other inflammatory severe respiratory diseases. Trial registrations EudraCT 2022–000714-33, DRKS00031463.
- 16 September 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (11) , 5683-5695
Open AccessTiprelestat for treatment of hospitalized COVID-19: results of the double-blind randomized placebo-controlled COMCOVID trial
Introduction Tiprelestat (recombinant human elafin) reversibly inhibits human neutrophil elastase. This can reduce overactivity of this enzyme in COVID-19-patients and might prohibit further organ damage and progression to severe disease. This protein had yet not been tested in COVID-19 patients. Methods This prospective, multicenter, randomized, double-blind, placebo-controlled trial investigated Tiprelestat in adult patients hospitalized for COVID-19 in 7 hospitals in Germany between May 2023 and May 2024. Patients received 100 mg Tiprelestat or placebo twice a day for 7 days, or shorter if no longer hospitalized due to COVID-19. Data about efficacy, safety, and pharmacokinetic trough levels were collected over 29 days. Results A total of 296 patients were planned. Due to slow recruitment during the end of the pandemic, only 17 patients were finally included. Of these, 9 received Tiprelestat and 8 placebo. The mean treatment exposition was 9.1 ± 4.8 (SD, maximum 15) 30-min infusions with Tiprelestat and 7.8 ± 3.2 (maximum 14) with placebo. No relevant abnormalities in clinical or laboratory blood parameters were suspected to be caused by Tiprelestat. None of the Tiprelestat-treated patients developed severe COVID-19 (WHO Clinical Progression Scale ≥ 6). The number of days with any oxygen support tended to be lower in the Tiprelestat group (2.4 ± 3.6 days) compared to placebo (4.0 ± 6.2 days). Stable plasma trough levels of Tiprelestat were shown upon repeated administration for up to 7 days, even in patients with impaired renal function (eGFR > 31 to < 60 mL/min) as comorbidity. Conclusion Tiprelestat infused for 30 min twice daily in patients with moderate COVID-19 requiring hospitalization was well tolerated and appears to be safe. Beneficially, plasma trough levels of the drug over time were high and stable. The small sample size does not facilitate reliable statements about efficacy. Further studies are necessary including other inflammatory severe respiratory diseases. Trial registrations EudraCT 2022–000714-33, DRKS00031463.
- Open Access
- 4 June 2024
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 40 (1) , 2360066
Transfer of preclinical study data on the influence of cimicifuga racemosa on functional changes in the hippocampus during menopause
Menopausal transition in women involves complex neurobiochemical changes linked to ovarian dysfunction, resulting in symptoms like vasomotor symptoms (VMS), sleep disturbances, anxiety, and cognitive impairments. Hormone replacement therapy is the first-line treatment. However, many women are reluctant to use HRT or have contraindications toward HRT and seek for alternatives. Non-hormonal therapies with extracts of Cimicifuga racemosa rhizomes like the isopropanolic extract (iCR, black cohosh) offer a promising alternative. A preclinical pilot study exploring iCR's effects on gene expression in the hippocampus and hypothalamus of ovarectomized (OVX) rats mimicking menopausal conditions identified important signaling pathways and CNS-based contributions to the multitargeted modes of action of iCR. Especially in the hippocampus, iCR compensated effects of OVX on gene expression profiles. These changes are reflected by the genes AVPR1A, GAL, CALCA, HCRT, PNOC, ESR1, ESR2 and TAC3 contributing to the formation of hot flushes or thermoregulation as well as to secondary effects such as blood pressure, metabolism, hormonal regulation, homeostasis, mood regulation, neuroendocrine modulation, regulation of sleep and arousal, and in learning, memory and cognition. To understand the mechanisms in the brain of estrogen-depressed animals (OVX) and subsequent iCR treatment we combined the results of the pilot study with those of up-to-date literature and tried to transfer the current knowledge to humans during menopausal transition and adaptation. Focus was laid on changes in the hippocampal function, that is disturbed by hormonal fluctuations, but can also be brought back into balance by iCR.
- 4 June 2024
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 40 (1) , 2360066
Open AccessTransfer of preclinical study data on the influence of cimicifuga racemosa on functional changes in the hippocampus during menopause
Menopausal transition in women involves complex neurobiochemical changes linked to ovarian dysfunction, resulting in symptoms like vasomotor symptoms (VMS), sleep disturbances, anxiety, and cognitive impairments. Hormone replacement therapy is the first-line treatment. However, many women are reluctant to use HRT or have contraindications toward HRT and seek for alternatives. Non-hormonal therapies with extracts of Cimicifuga racemosa rhizomes like the isopropanolic extract (iCR, black cohosh) offer a promising alternative. A preclinical pilot study exploring iCR's effects on gene expression in the hippocampus and hypothalamus of ovarectomized (OVX) rats mimicking menopausal conditions identified important signaling pathways and CNS-based contributions to the multitargeted modes of action of iCR. Especially in the hippocampus, iCR compensated effects of OVX on gene expression profiles. These changes are reflected by the genes AVPR1A, GAL, CALCA, HCRT, PNOC, ESR1, ESR2 and TAC3 contributing to the formation of hot flushes or thermoregulation as well as to secondary effects such as blood pressure, metabolism, hormonal regulation, homeostasis, mood regulation, neuroendocrine modulation, regulation of sleep and arousal, and in learning, memory and cognition. To understand the mechanisms in the brain of estrogen-depressed animals (OVX) and subsequent iCR treatment we combined the results of the pilot study with those of up-to-date literature and tried to transfer the current knowledge to humans during menopausal transition and adaptation. Focus was laid on changes in the hippocampal function, that is disturbed by hormonal fluctuations, but can also be brought back into balance by iCR.
- 10 August 2021
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 305 (1) , 287-290
Correction to: Gene expression analyses on multi‑target mode of action of black cohosh in menopausal complaints – a pilot study in rodents
- 10 August 2021
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 305 (1) , 287-290
Correction to: Gene expression analyses on multi‑target mode of action of black cohosh in menopausal complaints – a pilot study in rodents
- Open Access
- 14 July 2021
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 305 (1) , 275-286
Gene expression analyses on multi-target mode of action of black cohosh in menopausal complaints – a pilot study in rodents
Purpose: This study aimed at assessing gene expression profiles in hippocampus and hypothalamus of ovariectomized (OVX) rats with or without treatment with an isopropanolic extract of Cimicifuga racemosa rhizomes (iCR) in comparison to intact rats. Methods: Exploration of hippocampal (Hi) and hypothalamic (Hy) tissue from Sprague Dawley rats: without OVX (NHi = NHy = 4), tissues 3 months after OVX (NHi = 4, NHy = 3), or tissues of rats after their treatment with iCR for 3 months after OVX (NHi = NHy = 2). Gene expression profiles in these tissues were investigated by RNA-microarray-analysis and subsequent verification by qPCR. Results: 4812 genes were differentially regulated when comparing the three groups in hippocampus and hypothalamus. iCR compensated the effects of OVX in 518 genes. This compensatory effect was most prominent in hippocampal signalling pathways, thereof genes (GAL, CALCA, HCRT, AVPR1A, PNOC, etc.) involved in thermoregulation, regulation of sleep and arousal, blood pressure regulation, metabolism, nociception, hormonal regulation, homeostasis, learning and cognition, mood regulation, neuroendocrine modulation, etc.. In the hypothalamus, iCR compensated OVX-effects at TAC3 and OPRM1 but not at KISS1. These genes are involved in the pathophysiology of hot flashes. Conclusions: Our pilot study findings support a multifaceted mode of action of iCR in menopausal complaints on a tissue-specific brain gene expression level.
- 14 July 2021
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 305 (1) , 275-286
Open AccessGene expression analyses on multi-target mode of action of black cohosh in menopausal complaints – a pilot study in rodents
Purpose: This study aimed at assessing gene expression profiles in hippocampus and hypothalamus of ovariectomized (OVX) rats with or without treatment with an isopropanolic extract of Cimicifuga racemosa rhizomes (iCR) in comparison to intact rats. Methods: Exploration of hippocampal (Hi) and hypothalamic (Hy) tissue from Sprague Dawley rats: without OVX (NHi = NHy = 4), tissues 3 months after OVX (NHi = 4, NHy = 3), or tissues of rats after their treatment with iCR for 3 months after OVX (NHi = NHy = 2). Gene expression profiles in these tissues were investigated by RNA-microarray-analysis and subsequent verification by qPCR. Results: 4812 genes were differentially regulated when comparing the three groups in hippocampus and hypothalamus. iCR compensated the effects of OVX in 518 genes. This compensatory effect was most prominent in hippocampal signalling pathways, thereof genes (GAL, CALCA, HCRT, AVPR1A, PNOC, etc.) involved in thermoregulation, regulation of sleep and arousal, blood pressure regulation, metabolism, nociception, hormonal regulation, homeostasis, learning and cognition, mood regulation, neuroendocrine modulation, etc.. In the hypothalamus, iCR compensated OVX-effects at TAC3 and OPRM1 but not at KISS1. These genes are involved in the pathophysiology of hot flashes. Conclusions: Our pilot study findings support a multifaceted mode of action of iCR in menopausal complaints on a tissue-specific brain gene expression level.
- 9 September 2019
- Published by Georg Thieme Verlag KG in Zeitschrift für Phytotherapie
- Vol. 40 (S 01) , P02
Neuromodulating Action of Cimicifuga racemosa for Alleviation of Vasomotor Symptoms
Menopausal transition makes 50 to 85% of women experience symptoms affecting their well-being and quality of life. Licensed Cimicifuga racemosa (CR) medicinal products are efficacious against vasomotor symptoms (VMS), with isopropanolic extract (iCR) exhibiting best evidence [1, 2]. The mode of action is not fully known as the pathophysiology of VMS is still unclear. Circulating peripheral estrogen levels are not correlated with VMS [3]. The pace of estrogen depletion causes imbalances of serotonin- and noradrenalin levels (and others) in the thermoregulatory center, resulting in VMS [4 – 7]. The hypothalamic thermoregulatory center appears to be the most likely site of thermoregulatory dysfunction [8]. Hypothalamic KNDy neurons seem to participate in the generation of hot flushes [9]. Transformations in the postmenopausal brain include upregulation of KISS1 and TAC3 mRNA (encoding the KNDy-peptides kisspeptin and neurokinin) in distinct hypothalamic nuclei [10]. Also, calcitonin gene-related peptide seems to be involved in menopausal VMS [11]. References (e.g. MEDLINE, EMBASE, BIOSIS) was collected till 2019 and analyzed for CR interacting with brain receptors or modulating brain activity and brain metabolism. iCR alleviates ovariectomy (OVX)-induced impaired thermoregulation [12]. iCR binds to serotonin, dopamine, GABA and µ-opioid brain receptors leading to receptor-mediated functional activity [13 – 16]. CR/iCR modulates the ratio of cerebral monoamines and metabolites [17] as well as serotonergic and dopaminergic brain activity (EEG) [18] and µ-opioid receptor availability [19]. In addition, iCR ameliorates OVX-induced changes of the serotonergic and noradrenergic brainstem-preoptic anterior hypothalamus pathways [20, 21]. OVX reduced the adaptability of hypothalamic neurons to respond to temperature changes and iCR compensated these changes by increasing neuronal activity [4, 22]. Moreover iCR/CR exerts anti-inflammatory, antioxidant and radical scavenger activity [23 – 28]. In distinct brain regions, iCR compensates OVX-induced upregulation of genes relevant for thermoregulation, mood, cognition and other menopause-associated dysfunctions [29]. These CR properties may be important as estrogen decline and fluctuations cause oxidative stress and neuroinflammation, resulting in „dysregulation” in the hypothalamic thermoregulatory area and possibly other central brain regions (e.g. hippocampus). We hypothesize that CR/iCR is able to initiate functional recovery of the hypothalamic thermo-regulatory area and thus, to mitigate VMS by a multifaceted set of mechanisms. These may include a direct action on serotonin, dopamine and µ-opioid receptors in connection with modulation of VMS-relevant gene expression and anti-inflammatory, antioxidant and radical scavenger activities. The data show a non-estrogenic multi-target mode of action of CR alleviating menopausal symptoms including VMS. iCR binds to CNS receptors, modulates neuropeptide-based pathways, brain function and metabolism involved in thermoregulation and other climacteric symptoms. Further research is ongoing to elucidate the neuromodulating action of CR. References: [1] Beer AM, Neff A. Evid Based Complement Alternat Med 2013; 2013: 860602 [2] Beer AM et al. Gynecol Endocrinol 2013; 29: 1022 – 1025 [3] Sturdee DW et al. Climacteric 2017; 20: 296 – 305 [4] Hui Z et al. J Ethnopharmacol 2012; 142: 769 – 775 [5] Garcia de Arriba S et al. Z Phytother 2013; 34(Suppl.1): S29 [6] Danilovich N. Exp Neurol 2003; 183: 559 – 572 [7] Benedusi V et al. Endocrinology 2012; 153: 2777 – 2788 [8] Freedman RR. Am J Med 2005; 118: 124 – 130 [9] Rance NE et al. Front Neuroendocrinol 2013; 34: 211 – 227 [10] Skorupskaite K et al. Neuroendocrinology 2018; 106: 148 – 157 [11] Oliveira MA et al. Endocrine 2019; 63: 193 – 203 [12] Ma X et al. J Ethnopharmacol 2011; 138: 156 – 161 [13] Burdette JE et al. J Agric Food Chem 2003; 51: 5661 – 5670 [14] Powell SL et al. J Agric Food Chem 2008; 56: 11718 – 11726 [15] Nisslein T et al. Maturitas 2006; 54: S65 [16] Rhyu MR et al. J Agric Food Chem 2006; 54: 9852 – 9857 [17] Nadaoka I et al. Natural Product Communications 2012; 7: 15 – 18 [18] Garcia de Arriba S et al. Maturitas 2015; 82: 318 [19] Reame NE et al. Menopause 2008; 15: 832 – 840 [20] Wang W et al. Neuroendocrinology 2015; 101: 120 – 132 [21] Wang W et al. Ann Anat 2016; 208: 31 – 39 [22] Ma X et al. J Int Obstet Gynecol 2011; 38: 148 – 154 [23] Burdette JE et al. J Agric Food Chem 2002; 50: 7022 – 7028 [24] Nuntanakorn P et al. J Nat Prod 2006; 69: 314 – 318 [25] Kim SJ, Kim MS. Phytother Res 2000; 14: 596 – 600 [26] Schmid D et al. J Pharm Pharmacol 2009; 61: 1089 – 1096 [27] Schmid D et al. Can J Physiol Pharmacol 2009; 87: 963 – 972 [28] Da Y et al. PLoS One 2015; 10: e0121470 [29] Stute P. Latest insights into iCR's mode of action. Congress of European Menopause and Andropause Society. Berlin
- 9 September 2019
- Published by Georg Thieme Verlag KG in Zeitschrift für Phytotherapie
- Vol. 40 (S 01) , P02
Neuromodulating Action of Cimicifuga racemosa for Alleviation of Vasomotor Symptoms
Menopausal transition makes 50 to 85% of women experience symptoms affecting their well-being and quality of life. Licensed Cimicifuga racemosa (CR) medicinal products are efficacious against vasomotor symptoms (VMS), with isopropanolic extract (iCR) exhibiting best evidence [1, 2]. The mode of action is not fully known as the pathophysiology of VMS is still unclear. Circulating peripheral estrogen levels are not correlated with VMS [3]. The pace of estrogen depletion causes imbalances of serotonin- and noradrenalin levels (and others) in the thermoregulatory center, resulting in VMS [4 – 7]. The hypothalamic thermoregulatory center appears to be the most likely site of thermoregulatory dysfunction [8]. Hypothalamic KNDy neurons seem to participate in the generation of hot flushes [9]. Transformations in the postmenopausal brain include upregulation of KISS1 and TAC3 mRNA (encoding the KNDy-peptides kisspeptin and neurokinin) in distinct hypothalamic nuclei [10]. Also, calcitonin gene-related peptide seems to be involved in menopausal VMS [11]. References (e.g. MEDLINE, EMBASE, BIOSIS) was collected till 2019 and analyzed for CR interacting with brain receptors or modulating brain activity and brain metabolism. iCR alleviates ovariectomy (OVX)-induced impaired thermoregulation [12]. iCR binds to serotonin, dopamine, GABA and µ-opioid brain receptors leading to receptor-mediated functional activity [13 – 16]. CR/iCR modulates the ratio of cerebral monoamines and metabolites [17] as well as serotonergic and dopaminergic brain activity (EEG) [18] and µ-opioid receptor availability [19]. In addition, iCR ameliorates OVX-induced changes of the serotonergic and noradrenergic brainstem-preoptic anterior hypothalamus pathways [20, 21]. OVX reduced the adaptability of hypothalamic neurons to respond to temperature changes and iCR compensated these changes by increasing neuronal activity [4, 22]. Moreover iCR/CR exerts anti-inflammatory, antioxidant and radical scavenger activity [23 – 28]. In distinct brain regions, iCR compensates OVX-induced upregulation of genes relevant for thermoregulation, mood, cognition and other menopause-associated dysfunctions [29]. These CR properties may be important as estrogen decline and fluctuations cause oxidative stress and neuroinflammation, resulting in „dysregulation” in the hypothalamic thermoregulatory area and possibly other central brain regions (e.g. hippocampus). We hypothesize that CR/iCR is able to initiate functional recovery of the hypothalamic thermo-regulatory area and thus, to mitigate VMS by a multifaceted set of mechanisms. These may include a direct action on serotonin, dopamine and µ-opioid receptors in connection with modulation of VMS-relevant gene expression and anti-inflammatory, antioxidant and radical scavenger activities. The data show a non-estrogenic multi-target mode of action of CR alleviating menopausal symptoms including VMS. iCR binds to CNS receptors, modulates neuropeptide-based pathways, brain function and metabolism involved in thermoregulation and other climacteric symptoms. Further research is ongoing to elucidate the neuromodulating action of CR. References: [1] Beer AM, Neff A. Evid Based Complement Alternat Med 2013; 2013: 860602 [2] Beer AM et al. Gynecol Endocrinol 2013; 29: 1022 – 1025 [3] Sturdee DW et al. Climacteric 2017; 20: 296 – 305 [4] Hui Z et al. J Ethnopharmacol 2012; 142: 769 – 775 [5] Garcia de Arriba S et al. Z Phytother 2013; 34(Suppl.1): S29 [6] Danilovich N. Exp Neurol 2003; 183: 559 – 572 [7] Benedusi V et al. Endocrinology 2012; 153: 2777 – 2788 [8] Freedman RR. Am J Med 2005; 118: 124 – 130 [9] Rance NE et al. Front Neuroendocrinol 2013; 34: 211 – 227 [10] Skorupskaite K et al. Neuroendocrinology 2018; 106: 148 – 157 [11] Oliveira MA et al. Endocrine 2019; 63: 193 – 203 [12] Ma X et al. J Ethnopharmacol 2011; 138: 156 – 161 [13] Burdette JE et al. J Agric Food Chem 2003; 51: 5661 – 5670 [14] Powell SL et al. J Agric Food Chem 2008; 56: 11718 – 11726 [15] Nisslein T et al. Maturitas 2006; 54: S65 [16] Rhyu MR et al. J Agric Food Chem 2006; 54: 9852 – 9857 [17] Nadaoka I et al. Natural Product Communications 2012; 7: 15 – 18 [18] Garcia de Arriba S et al. Maturitas 2015; 82: 318 [19] Reame NE et al. Menopause 2008; 15: 832 – 840 [20] Wang W et al. Neuroendocrinology 2015; 101: 120 – 132 [21] Wang W et al. Ann Anat 2016; 208: 31 – 39 [22] Ma X et al. J Int Obstet Gynecol 2011; 38: 148 – 154 [23] Burdette JE et al. J Agric Food Chem 2002; 50: 7022 – 7028 [24] Nuntanakorn P et al. J Nat Prod 2006; 69: 314 – 318 [25] Kim SJ, Kim MS. Phytother Res 2000; 14: 596 – 600 [26] Schmid D et al. J Pharm Pharmacol 2009; 61: 1089 – 1096 [27] Schmid D et al. Can J Physiol Pharmacol 2009; 87: 963 – 972 [28] Da Y et al. PLoS One 2015; 10: e0121470 [29] Stute P. Latest insights into iCR's mode of action. Congress of European Menopause and Andropause Society. Berlin
- 23 November 2006
- Published by Georg Thieme Verlag KG in Zeitschrift für Phytotherapie
- Vol. 27 (S 1) , V13
Einfluss iCR-haltiger Cimicifuga-Präparate auf das rezidivfreie Überleben von Brustkrebspatientinnen
Der isopropanolische Cimicifuga-racemosa-Extrakt (iCR, enthalten in Remifemin® und Remifemin® plus) wirkt gegen Wechseljahresbeschwerden. Seine Sicherheit bei Brustkrebsüberlebenden, einschließlich Östrogen-abhängiger Tumoren, hinsichtlich des rezidivfreien Überlebens untersuchten wir mittels dieser pharmakoepidemiologischen retrospektiven Kohortenstudie. Die Daten stammen aus allgemeinen, gynäkologischen sowie internistischen Praxen in Deutschland, die der IMS-Datenbank Mediplus angeschlossen sind. Der Hauptzielparameter war das rezidivfreie Überleben. Der Einfluss einer iCR-Therapie bei Brustkrebsüberlebenden wurde mittels Cox-Regressionen analysiert, in die das Alter, die Tamoxifen-Anwendung sowie weitere Einflussgrößen einbezogen wurden und die relative Hazard-Raten lieferten. Von 18861 Patientinnen hatten 1102 iCR durchschnittlich 1,5 Jahre erhalten. Die mittlere Beobachtungsdauer betrug 3,6 Jahre. iCR war mit einem signifikant längeren rezidivfreien Überleben assoziiert. Zwei Jahre nach der Initialdiagnose hatten 14% der Kontrollgruppe ein Rezidiv entwickelt, während die iCR-Gruppe diese Rezidivrate erst nach 6,5 Jahren erreichte. Das primäre Cox-Regressionsmodell ergab für das rezidivfreie Überleben eine relative Hazard-Rate von 0,83 zu Gunsten der iCR-Gruppe (95%-Konfidenzintervall 0,69–0,99). Dieses Ergebnis erwies sich als konsistent in allen Variationen des statistischen Modells, einschließlich Subgruppenanalysen. Der TNM-Status der Patientinnen war zwar unbekannt, doch da er die iCR-Therapie-Entscheidung nicht beeinflusst, ist seine gleichmäßige Verteilung auf die Gruppen annehmbar. Die Datenbank wies eine gute interne und externe Validität auf. Das rezidivfreie Überleben von Brustkrebspatientinnen wird durch iCR-haltige Arzneimittel nicht negativ beeinflusst.
- 23 November 2006
- Published by Georg Thieme Verlag KG in Zeitschrift für Phytotherapie
- Vol. 27 (S 1) , V13
Einfluss iCR-haltiger Cimicifuga-Präparate auf das rezidivfreie Überleben von Brustkrebspatientinnen
Der isopropanolische Cimicifuga-racemosa-Extrakt (iCR, enthalten in Remifemin® und Remifemin® plus) wirkt gegen Wechseljahresbeschwerden. Seine Sicherheit bei Brustkrebsüberlebenden, einschließlich Östrogen-abhängiger Tumoren, hinsichtlich des rezidivfreien Überlebens untersuchten wir mittels dieser pharmakoepidemiologischen retrospektiven Kohortenstudie. Die Daten stammen aus allgemeinen, gynäkologischen sowie internistischen Praxen in Deutschland, die der IMS-Datenbank Mediplus angeschlossen sind. Der Hauptzielparameter war das rezidivfreie Überleben. Der Einfluss einer iCR-Therapie bei Brustkrebsüberlebenden wurde mittels Cox-Regressionen analysiert, in die das Alter, die Tamoxifen-Anwendung sowie weitere Einflussgrößen einbezogen wurden und die relative Hazard-Raten lieferten. Von 18861 Patientinnen hatten 1102 iCR durchschnittlich 1,5 Jahre erhalten. Die mittlere Beobachtungsdauer betrug 3,6 Jahre. iCR war mit einem signifikant längeren rezidivfreien Überleben assoziiert. Zwei Jahre nach der Initialdiagnose hatten 14% der Kontrollgruppe ein Rezidiv entwickelt, während die iCR-Gruppe diese Rezidivrate erst nach 6,5 Jahren erreichte. Das primäre Cox-Regressionsmodell ergab für das rezidivfreie Überleben eine relative Hazard-Rate von 0,83 zu Gunsten der iCR-Gruppe (95%-Konfidenzintervall 0,69–0,99). Dieses Ergebnis erwies sich als konsistent in allen Variationen des statistischen Modells, einschließlich Subgruppenanalysen. Der TNM-Status der Patientinnen war zwar unbekannt, doch da er die iCR-Therapie-Entscheidung nicht beeinflusst, ist seine gleichmäßige Verteilung auf die Gruppen annehmbar. Die Datenbank wies eine gute interne und externe Validität auf. Das rezidivfreie Überleben von Brustkrebspatientinnen wird durch iCR-haltige Arzneimittel nicht negativ beeinflusst.